Alzheimer's is a disease of many cells and their interactions, not just one dysfunctional cell
In a study of remarkable technical scale, researchers at Columbia University and the Hebrew University of Jerusalem have mapped the cellular choreography of early Alzheimer's disease — tracing not merely which brain cells fail, but the precise order in which they betray one another. By reading the genetic activity of 1.6 million individual cells drawn from over 400 donated brains, the team has reframed Alzheimer's not as the breakdown of a single component, but as the collapse of a community. The work arrives as a quiet but consequential shift in how medicine might one day intervene — not with a single cure, but with the wisdom to interrupt a conversation before it turns catastrophic.
- Alzheimer's has long resisted treatment in part because researchers were searching for a single culprit — this study reveals the disease is a cascading dialogue among multiple cell types, making that search fundamentally incomplete.
- Two specific microglial cell populations appear to fire first, triggering the buildup of amyloid and tau proteins before any cognitive symptoms emerge — a window of intervention that has largely gone unrecognized.
- Astrocytes then enter the cascade, dismantling the electrical networks neurons depend on for communication and recruiting further cellular accomplices, accelerating the collapse toward dementia.
- Crucially, the study identifies a second aging pathway — one that does not lead to Alzheimer's — suggesting that cognitive decline is not an inevitable destination of growing old.
- The findings point toward therapies that would modify entire cellular communities at early disease stages, shifting the goal from halting damage already done to preventing the cascade from beginning.
A team led by Columbia neurologist Philip De Jager has produced one of the most detailed maps yet of how Alzheimer's disease begins — not by identifying a single failing molecule, but by tracing the sequence of cellular relationships that carry a brain from health into decline. Working with tissue from over 400 donated brains, all from participants in long-running cognitive aging studies at Rush University, the researchers applied single-cell RNA sequencing to 1.6 million individual cells, reading the active genes within each one to reconstruct the disease's earliest movements.
What emerged was a portrait of Alzheimer's as a community breakdown. Two types of microglial cells — the brain's immune sentinels — appear to initiate the accumulation of amyloid and tau, the proteins long associated with the disease. Once that pathology takes hold, astrocytes move in, disrupting the electrical connectivity between neurons and drawing in additional cell types. The result is a profound rewiring of brain function that eventually surfaces as cognitive impairment.
Perhaps equally significant is what the study found running alongside this pathological cascade: a separate cellular pathway through which the aging brain can travel without developing Alzheimer's at all. This suggests that dementia is not an inevitable consequence of growing old, and that understanding what steers a brain toward the healthier trajectory could unlock protective strategies.
De Jager frames the disease as emerging from the interactions among multiple cell types rather than the failure of any single one — a reframing with real therapeutic consequences. Future interventions, the study implies, may need to address entire cellular communities, interrupting the conversation between microglia and astrocytes before the cascade becomes irreversible. The challenge now is translating this cellular map into treatments that can reach the brain early enough to matter.
Researchers have mapped the cellular landscape of early Alzheimer's disease by examining 1.6 million individual brain cells from older adults, a technical feat that reveals not just which cells go wrong, but the precise sequence in which they fail. The work, led by Columbia neurologist Philip De Jager alongside colleagues at Columbia University and the Hebrew University of Jerusalem, suggests that Alzheimer's is fundamentally a disease of cellular communities—cells talking to each other, amplifying dysfunction, cascading toward cognitive collapse. This distinction matters because it opens new possibilities for intervention at specific points along the disease's progression, before irreversible damage takes hold.
The study drew on brain tissue from over 400 donors, all of whom had participated in the Religious Orders Study and the Memory & Aging Project, long-running research efforts based at Rush University in Chicago. These donors had been carefully tracked throughout their lives, their cognitive abilities documented, their brains preserved after death. From each brain, researchers extracted thousands of cells from regions known to deteriorate in Alzheimer's and aging. Each cell then underwent single-cell RNA sequencing, a molecular technique that reads which genes are active within that individual cell—a snapshot of its functional state. The resulting dataset of 1.6 million cells was then processed through machine-learning algorithms developed by Vilas Menon and Naomi Habib to identify cell types and map their interactions.
Previous research had identified molecules implicated in Alzheimer's, but those studies worked with whole brain samples, losing all sense of which specific cells were involved at which stages of disease. The new approach, by contrast, reconstructs the trajectory of brain aging from its earliest detectable changes. Because the donors represented different points along the disease spectrum—some cognitively normal, some in early decline, some with full Alzheimer's—the researchers could distinguish the cellular changes that accompany normal aging from those that drive pathology.
The findings point to a specific sequence of cellular events. Two types of microglial cells, which serve as immune sentries in the brain, appear to initiate the accumulation of amyloid and tau proteins—the hallmark pathological markers of Alzheimer's disease. But the damage doesn't stop there. Once this pathology has accumulated, a different cell type called astrocytes enters the picture and begins to disrupt the electrical connectivity that allows neurons to communicate. These astrocytes recruit additional cell types, and the result is a profound rewiring of brain function that manifests as cognitive impairment.
Equally important, the study identified a second community of cells that guides the aging brain along a different path—one that does not lead to Alzheimer's disease. This distinction is crucial. It suggests that aging itself is not a one-way street toward dementia. Some brains age without developing Alzheimer's pathology, and understanding why could reveal protective mechanisms or alternative cellular trajectories worth pursuing therapeutically.
De Jager emphasizes that the disease emerges from interactions among multiple cell types, not from the dysfunction of a single cell population. This reframes how researchers and clinicians should think about treatment. Rather than targeting one molecule or one cell type, interventions might need to modify entire cellular communities—to interrupt the conversation between microglial cells and astrocytes, or to prevent astrocytes from recruiting their downstream partners. The study reveals specific points in this sequence where such intervention might be possible, before the cascade becomes irreversible.
The implications extend beyond basic science. If researchers can identify which cellular communities are pathogenic in a given individual, they might be able to restore those cells to a healthy state, or prevent their dysfunction in the first place. This moves Alzheimer's research from a search for a single silver bullet toward a more nuanced understanding of disease as a process unfolding across multiple cell types over time. The next phase will be translating these cellular insights into therapies that can reach the brain and modify these communities before cognitive decline becomes apparent.
Notable Quotes
We may need to modify cellular communities to preserve cognitive function, and our study reveals points along the sequence of events leading to Alzheimer's where we may be able to intervene.— Philip De Jager, Columbia neurologist
The Hearth Conversation Another angle on the story
Why does it matter that you can look at individual cells instead of whole brain samples?
Because Alzheimer's isn't one cell breaking down—it's a cascade. When you look at the whole brain at once, you lose the sequence. You can't tell which cell started the problem, which cells responded to it, which cells made it worse. Now we can see the order of events.
So you're saying some brains age without getting Alzheimer's. What's different about them?
That's the question. The study found two different cellular communities in aging brains. One leads toward Alzheimer's pathology. The other doesn't. We don't yet know what protects the second group, but now we know to look for it.
The microglial cells start it, then astrocytes amplify it. Can you stop it at either point?
Theoretically, yes. If you can interrupt the microglial cells before they accumulate amyloid and tau, you might prevent the whole cascade. Or if you catch it after that but before astrocytes disrupt the electrical wiring, you might still preserve cognitive function. The study maps where those intervention points are.
Does this mean a drug that targets microglia would work for everyone?
Not necessarily. The study suggests we might need to modify cellular communities in each individual. What's pathogenic in one person's brain might be different from another's. That's why understanding the sequence matters—it lets you intervene at the right point for that person.
How confident are you in these findings?
The dataset is enormous—1.6 million cells from over 400 brains. The donors were tracked their whole lives, so we know their actual cognitive state. The machine learning was rigorous. But this is still mapping the territory. The next step is testing whether you can actually intervene at these points and change the outcome.